Gemfibrozil in the Treatment of Dyslipidaemias in Middle‐Aged Male Survivors of Myocardial Infarction

Publisher Website
Google Scholar
Abstract
The effects of gemfibrozil on serum lipids and apolipoproteins were investigated in 60 male survivors of myocardial infarction (MI) (and range 29-48 yr, mean 44). Fifteen had normal serum cholesterol (.ltoreq. 7.0 mmol/l) and triglyceride (.ltoreq. 1.7 mmol/l) levels, but most had low levels of high density lipoprotein (HDL) cholesterol (< 1.00 mmol/l). Ten had type II A, 27 type II B and 8 type IV hyperlipidemia. A double-blind placebo-controlled cross-over design was used with 3 mo. treatment periods. Gemfibrozil was given in daily doses of 1200 mg. The drug was well tolerated and there were no drop-outs attributable to its use. In all subjects, gemfibrozil reduced the mean serum total cholesterol by 17% and triglycerides by 54% and increased HDL cholesterol by 16%. The percentage HDL cholesterol of total cholesterol increased from 14-19%. The changes were similar in patients with normal serum cholesterol and triglyceride values and in those with classical hyperlipidemias. The changes during placebo treatment corresponded to those in healthy male untreated controls who were followed simultaneously. Apoprotein A-I remained unchanged, but A-II increased by 20% during gemfibrozil treatment. Gemfibrozil corrects effectively dyslipidemias in male MI patients but further long term studies are warranted.